Vanderbilt University Medical Center
vumc.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
820
Active
225
Phase 3
23
Total enrollment
796,273
Pipeline matrix
Showing 40 of 96 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ValACYclovir 1000 MG | — | — | — | — | — | 1 | |
| Shingrix | — | — | — | — | — | 1 | |
| Botulinum Toxin Type A Injection [Botox] | — | — | — | — | — | 1 | |
| Pimavanserin | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 300 mcg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 600 mcg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 900 mcg | — | — | — | — | — | 1 | |
| Buccal Placebo | — | — | — | — | — | 1 | |
| Oral Placebo | — | — | — | — | — | 1 | |
| Oral immediate-release oxycodone 10mg | — | — | — | — | — | 1 | |
| Buccal Buprenorphine 450mcg | — | — | — | — | — | 1 | |
| Botulinum toxin type A | — | — | — | — | — | 1 | |
| GlyNAC | — | — | — | — | — | 1 | |
| Lidocaine HCl 0.8% in D5W | — | — | — | — | — | 1 | |
| Vericiguat | — | — | — | — | — | 1 | |
| Hydroxyurea | — | — | 5 | ||||
| Sodium Chloride 0.9% | — | — | — | — | 2 | ||
| Icatibant | — | — | — | 5 | |||
| Dexmedetomidine | — | — | — | 4 | |||
| Polyethylene Glycol 3350 | — | — | — | — | — | 1 | |
| Deutetrabenazine | — | — | — | — | — | 1 | |
| Nitric Oxide | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Artificial Tears Methylcellulose | — | — | — | — | — | 1 | |
| Midazolam | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | 3 | ||
| 2-Hydroxybenzylamine | — | — | — | — | — | 3 | |
| Theophylline | — | — | — | — | — | 3 | |
| Transdermal Nicotine patch | — | — | — | — | — | 3 | |
| High Dose Quadrivalent Inactivated Influenza Vaccine | — | — | — | — | — | 2 | |
| Standard Dose Quadrivalent Inactivated Influenza Vaccine | — | — | — | — | — | 2 | |
| Moxonidine | — | — | — | — | 2 | ||
| Saline | 9 | ||||||
| Placebos | — | — | — | 4 | |||
| Amlodipine | — | — | — | — | 2 | ||
| Galantamine | — | — | — | — | 3 | ||
| Empagliflozin 25 MG | — | — | — | — | — | 2 | |
| CO2 gel mask | — | — | — | — | — | 1 | |
| RhPDGF-BB | — | — | — | — | — | 1 | |
| Protocolized diuretic therapy | — | — | — | — | — | 1 |
56 more active programs hidden
Next readouts
- 2025-10-30
- 2025-12-31
- 2025-12-31
- 2026-03-31
- 2026-04-17
- 2026-06
- 2026-06
- 2026-06
- 2026-06
- 2026-06-30
Top conditions
- Obesity30
- Hypertension15
- Delirium15
- Autism Spectrum Disorder14
- Parkinson Disease14
- Depression13
- Critical Illness12
- Diabetes Mellitus, Type 211
Frequently asked questions about Vanderbilt University Medical Center
- How many clinical trials does Vanderbilt University Medical Center have on ClinicalTrials.gov?
- Vanderbilt University Medical Center is listed as the lead sponsor on 820 clinical trials in ClinicalTrials.gov, 225 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vanderbilt University Medical Center's trials are in Phase 3?
- 23 of Vanderbilt University Medical Center's trials are in Phase 3, spread across 96 active drug programs.
- What therapeutic areas does Vanderbilt University Medical Center focus on?
- Vanderbilt University Medical Center's most-studied conditions on ClinicalTrials.gov are Obesity, Hypertension, Delirium, Autism Spectrum Disorder, Parkinson Disease.
- When are Vanderbilt University Medical Center's next clinical trial readouts?
- Vanderbilt University Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)”, expected around 2025-10-30.